The current study assists in defining therapeutic dose regimes potentially effective in AD patients and lower-dose CBD treatment would reduce not only the therapy costs for patients but also potential side effects (most important for therapeutic cannabis compounds containing not only CBD but also other cannabinoids such as Δ9-tetrahydrocannabinol, as would be the case for CBD-enriched cannabis extract therapies). This evidence concerns the gene OPN1MW and Alzheimer disease.